FDA OKs Merck combo antibiotic for bacterial pneumonia

Under Fast Track, Priority Review and Qualified Infectious Disease Program status, the FDA approves Merck’s (NYSE:MRK) Recarbrio (imipenem, cilastatin, relebactam) for adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

The combo antibiotic was first approved in the U.S. in July 2019 for complicated urinary tract and complicated intra-abdominal bacterial infections.

https://seekingalpha.com/news/3580626-fda-oks-merck-combo-antibiotic-for-bacterial-pneumonia